"Step change" Yervoy from BMS not cost effective for NICE: may need biomarker test
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has recognised Bristol-Myers Squibb's Yervoy (ipilimumab) as a "step change" in the treatment of advanced melanoma, according to draft guidance published on 14 October. Despite this, Yervoy would not be a cost-effective use of NHS resources due to uncertainty over its long-term benefits and, in the absence of a biomarker, the patient populations it could help, says the institute.
You may also be interested in...
Australian Industry Maps Path To Better Use Of Real World Evidence
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
Decision On Covid-19 TRIPS Waiver Postponed
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Need a specific report? 1000+ reports available
Buy Reports